← All Spyre Therapeutics, INC filings

Spyre Therapeutics, INC DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
SYRE
Spyre Therapeutics, INC
DEF: Spyre Therapeutics Schedules 2026 Annual Meeting
Spyre Therapeutics announces its 2026 Annual Meeting of Stockholders to be held virtually on May 27, 2026, with key proposals including director elections and executive compensation.
NASDAQ
SYRE
Spyre Therapeutics, INC
DEFA14A: Spyre Therapeutics Files Definitive Proxy Statement with SEC
Spyre Therapeutics has filed a definitive proxy statement with the Securities and Exchange Commission.
NASDAQ
SYRE
Spyre Therapeutics, INC
DEF: Spyre Therapeutics Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals
Spyre Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on May 29, 2025, to vote on director elections, executive compensation, and auditor ratification.
NASDAQ
SYRE
Spyre Therapeutics, INC
DEF 14A: Spyre Therapeutics Announces 2024 Annual Meeting of Stockholders
Spyre Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on May 13, 2024, to vote on key proposals including director elections, executive compensation, auditor ratification, and stock issuance approvals.